Recommendation ID
CG182/2
Question
For people with CKD at the highest risk of cardiovascular disease, what is the clinical effectiveness of low-dose aspirin compared with placebo for primary prevention of cardiovascular disease?
Any explanatory notes
(if applicable)
Why this is important: CKD is a common long-term condition and a powerful independent predictor of cardiovascular disease. The risks are increased as the estimated glomerular filtration rate (eGFR) decreases and level of albuminuria increases. Kidney Disease: Improving Global Outcomes (KDIGO) classifies people with CKD as being at moderate risk, high risk or very high risk of cardiovascular disease according to their eGFR and albumin:creatinine ratio (ACR). However, the current evidence base for reducing cardiovascular risk in the CKD population is very limited.

Source guidance details

Comes from guidance
Chronic kidney disease in adults: assessment and management
Number
CG182
Date issued
July 2014

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 07/10/2014